This study was led by the Department of Hepatobiliary Surgery of the First Affiliated Hospital of the University of Science and Technology of China (USTC), in close cooperation with many participating units across the country, to establish a standardized clinical information database of hepatocellular carcinoma cohorts, which will provide a guarantee for conducting high-quality real-world clinical studies and clinical research.

Inclusion Criteria:

• Age ≥ 18 years, no gender limit
• Patients without surgery are initially diagnosed with hepatocellular carcinoma, intrahepatic cholangiocarcinoma, mixed hepatocellular carcinoma-cholangiocarcinoma, or metastatic hepatocellular carcinoma based on the results of imaging and laboratory tests, or patients with surgery are diagnosed with hepatocellular carcinoma, intrahepatic cholangiocarcinoma, mixed hepatocellular carcinoma-cholangiocarcinoma, or metastatic hepatocellular carcinoma based on the results of pathologic tests
• Signed informed consent, good compliance, willingness to accept follow-up and provide blood and postoperative pathology residual samples

Exclusion Criteria:

• Combination of severe central nervous system disease, respiratory disease, autoimmune disease, chronic renal insufficiency, long-term use of immunosuppressive drugs, combination of severe uncontrolled infections
• Concurrent active cardiovascular disease, cerebrovascular accident within 6 months, myocardial infarction, unstable angina pectoris, or congestive heart failure of class II or greater according to the New York Heart Association criteria, severe arrhythmia requiring medication
• Pregnant or breastfeeding women
• Participation in other therapeutic clinical trials during the course of the patient's illness in which the treatment cannot be specified or information about the treatment cannot be collected

Patients diagnosed with hepatocellular carcinoma, intrahepatic cholangiocarcinoma, combined hepatocellular carcinoma-cholangiocarcinoma, or metastatic liver cancer.